The UK has approved a new weight loss pill called Foundayo, developed by Eli Lilly, which is also known for the injectable drug Mounjaro.

Context

This approval comes as part of a growing trend towards the use of GLP-1 receptor agonists for weight management.S1S2

Key points

• Foundayo is a GLP-1 pill that can be taken daily, unlike some injectable alternatives.S1S2

• The pill is designed for individuals with obesity or those who are overweight.S2

• Aleniglipron, the active ingredient in Foundayo, has shown promising results in clinical trials.S2

• Participants in trials lost up to 12.1% of their body weight over 36 weeks.S2

• The pill can be taken with or without food, offering flexibility for users.S2

• Foundayo may be easier to produce at scale compared to injectable drugs.S2

• Eli Lilly aims to expand its portfolio of weight management solutions with this approval.S1

• The approval reflects increasing interest in non-injectable weight loss options.S1

Why it matters

• The approval of Foundayo could provide a new option for those struggling with weight management.S1

• It highlights the shift towards oral medications in the obesity treatment landscape.S2

• The potential for easier production may improve accessibility for patients.S2

What to watch

• Monitor the market response to Foundayo's launch in the UK.S1

• Watch for further studies on the long-term effects of aleniglipron.S2

• Keep an eye on Eli Lilly's future developments in weight management drugs.S1